Substance / Medication

Enasidenib

Overview

Active Ingredient
enasidenib
RxNorm CUI
1940332

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Cost-effectiveness of Enasidenib versus conventional care for older patients withmutant refractory/relapsed AML.
Alhajahjeh Abdulrahman, Patel Kishan K, Shallis Rory M et al. · Leuk Lymphoma · 2025
PMID: 39560957TrialFull text (PMC)
Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.
Risueño Alberto, See Wendy L, Bluemmert Iryna et al. · Leuk Res · 2024
PMID: 38564986Trial
Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies.
Fathi Amir T, Kim Haesook T, Soiffer Robert J et al. · Blood Adv · 2022
PMID: 36150050TrialFull text (PMC)
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Stein Eytan M, DiNardo Courtney D, Fathi Amir T et al. · Blood · 2021
PMID: 33024987TrialFull text (PMC)
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
Stein Eytan M, Fathi Amir T, DiNardo Courtney D et al. · Lancet Haematol · 2020
PMID: 32145771Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Enasidenib (substance)
SNOMED CT
763038001
UMLS CUI
C4519428
RxNorm CUI
1940332

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.